Radionuclide therapy using the radioactive element terbium shows promising potential in treating lymphoma, according to recent experimental results from the Paul Scherrer Institute (PSI) in collaboration with Inselspital – Bern University Hospital.
Elisa Rioja-Blanco and Martin Béhé are jointly conducting research at the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. The researchers are now refining this type of therapy in order to carry out clinical trials.
Every year, almost 2,000 people in Switzerland are diagnosed with lymphoma, and about 570 of them die from the disease. Researchers at PSI’s Center for Radiopharmaceutical Sciences are now proposing a new therapy that could soon increase the chances of survival for many of those affected: radioimmunotherapy with the nuclide terbium-161.
“The radioactive isotope terbium-161 is attached to an antibody and injected into the bloodstream of the patient,” explains Martin Béhé from the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. This antibody latches onto a structure in the body that is particularly common in lymphoma cells: the CD30 receptor. “This brings the radioactive terbium directly to the site of the tumour to kill the cancer cells with its radioactive radiation.” Healthy organs in the body are spared, on the other hand.
In almost a third of all lymphoma patients, the tumour cells produce the CD30 receptor – in these patients the new treatment could be applied. The same is true of T-cell lymphomas, in which the T-lymphocytes of the immune system become cancerous – a disease that has until now been difficult to treat.
Radionuclide therapy is already well established in clinical practice. Hospitals currently carry out this form of cancer treatment with a different radioactive substance: the nuclide lutetium-177. This is used to treat prostate cancer and tumours arising from hormone-producing cells. Radioactive lutetium decays to produce high-energy, high-velocity electrons, called beta particles, which combat larger tumours effectively.
However, individual tumour cells and small clusters of cancer cells elude treatment with lutetium-177 and can lead to a recurrence of the disease. This makes this form of radionuclide therapy unsuitable for lymphoma. In this type of cancer, some of the tumour cells circulate in the bloodstream rather than existing as a larger, localisable tumour.
Terbium-161 has a decisive advantage over lutetium-177: in addition to beta particles, it also emits conversion and Auger electrons. “This radiation has a range of less than one micrometre, or one thousandth of a millimetre. This is the size of a tumour cell,” explains Martin Béhé. Hence, terbium-161 acts on its immediate surroundings, making it particularly suitable for the targeted treatment of smaller tumours.
“Terbium-161 fires more precise bullets, so to speak,” explains Elisa Rioja-Blanco, also from the Center for Radiopharmaceutical Sciences and first author of the study. Even individual cancer cells in the blood could be eliminated without causing severe side effects. “We can also catch small tumour foci that doctors may not even be aware of at the time.”
The isotope has a half-life of 6.9 days, which means that its effect is halved every 6.9 days. This is an advantage for radionuclide therapy: after manufacturing the drug, it can be transported to a hospital without losing too much of its activity on the way. On the other hand, the radiation level decreases rapidly after treatment within a reasonable period of time.
A powerful weapon against cancer cells
The PSI researchers led by Martin Béhé and Elisa Rioja-Blanco produced the active substance, consisting of terbium-161 and an antibody against the CD30 receptor, themselves at PSI. They then tested it in the laboratory on three types of cancer cells that produce CD30 receptors. They found that – depending on the type of cell – the substance was 2 to 43 times as effective at killing the cancer cells than the analogous substance using lutetium-177. Further experiments have shown that this is because the terbium-based drug caused more severe damage to the DNA in the cancer cell, which the cell itself is unable to repair.
The researchers then tested the drug on mice suffering from cancer. “This shows us where the substance accumulates in the body and whether it actually reaches tumours,” explains Elisa Rioja-Blanco. The substance was indeed preferentially absorbed by the tumour tissue. On average, mice treated with terbium-161 survived twice as long as their counterparts injected with a lutetium-177 drug. Some of the mice even ended up completely cancer-free after the treatment.
On the way to clinical trials
Terbium-161 is already being tested as an anti-cancer drug in several clinical trials – the PSI researchers have now for the first time scrutinised it as a potential treatment for lymphoma. “Our results are a good indication that the substance could also prove to be effective against lymphoma in humans,” says Elisa Rioja-Blanco. Clinical studies will hopefully soon show whether this is indeed the case.
The Lymphoma Challenge, organised by ETH Zurich, is providing financial support for the project. The team has now secured follow-on funding from Innosuisse to further investigate and optimise the drug so that it can be commercialised and tested in humans in the future.
Switzerland is aligning with the European Union's 17th sanctions package by adopting the listed measures in response to Russia's continued aggression against Ukraine. Measures came into force on June 3.
Switzerland has emerged as a key destination for Azerbaijani non-oil goods, with imports tripling in the first four months of 2025.
Switzerland’s economy outperformed expectations in Q1 2025, driven by a surge in exports to the United States and strong growth in the chemical and pharmaceutical sectors.
A massive glacial landslide in southern Switzerland has buried the village of Blatten, formed a dangerous lake by blocking the River Lonza, and raised fears of flooding downstream as emergency crews monitor the situation.
A massive glacier collapse has destroyed most of the Swiss village of Blatten, leaving one person missing and nearly the entire town buried under debris.
Wizz Air has suspended all flights to and from Tel Aviv, Israel, and its European services to Amman, Jordan, effective immediately until September 15 due to escalating situation in the Middle East. Also, the air carrier temporarily suspended its flights between Astana, Kazakhstan, and Abu Dhabi.
A nationwide transport strike on Friday disrupted travel across Italy, with major delays and cancellations reported in rail, air, and public transit services.
Azerbaijan and Poland discussed closer cooperation in digital tax reforms and innovation during a high-level meeting held on the sidelines of the IOTA General Assembly in Baku.
A 32°C heatwave expected to grip England has been made a 100 times more likely by human-caused climate change, according to a rapid scientific analysis released Thursday.
Kazakhstan’s flagship carrier, Air Astana, will temporarily suspend its flights from Atyrau to Dubai starting June 28, due to a significant increase in flight duration.
Iranian missiles struck multiple locations across Israel and neighbouring regions early Friday morning, including a Microsoft office complex, according to emergency responders and local media reports.
Peace is no longer a dream. It is a discussion. On the streets of Baku and Yerevan, it is also a question, of trust, of foreign interests, and of who truly wants it.
Israeli strikes have reportedly targeted areas near the residences of Iran’s Supreme Leader Ayatollah Ali Khamenei and President Masoud Pezeshkian, according to the New York Times, citing local witnesses.
The 2025 G7 Leaders’ Summit was held June 15–17 in Kananaskis, Alberta, under Canada’s presidency. Prime Minister Mark Carney framed the meeting around priorities of protecting communities, energy and climate security, the digital transition, and future partnerships.
Start your day informed with AnewZ Morning Brief: here are the top news stories for June 17th, covering the latest developments you need to know.
China has successfully mastered the technology to produce Yttrium-90, a critical medical isotope used in radiation therapy for liver cancer, within a commercial nuclear reactor.
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Revolutionizing Heart Care: How Artificial Intelligence Powered Digital Twins Are Shaping the Future of Medicine
Researchers at the University of Miami have discovered 230 new giant viruses in global ocean waters, shedding light on their hidden role in marine ecosystems and their potential impact on public health.
Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
Wizz Air has suspended all flights to and from Tel Aviv, Israel, and its European services to Amman, Jordan, effective immediately until September 15 due to escalating situation in the Middle East. Also, the air carrier temporarily suspended its flights between Astana, Kazakhstan, and Abu Dhabi.
A nationwide transport strike on Friday disrupted travel across Italy, with major delays and cancellations reported in rail, air, and public transit services.
Azerbaijan and Poland discussed closer cooperation in digital tax reforms and innovation during a high-level meeting held on the sidelines of the IOTA General Assembly in Baku.
A 32°C heatwave expected to grip England has been made a 100 times more likely by human-caused climate change, according to a rapid scientific analysis released Thursday.
Kazakhstan’s flagship carrier, Air Astana, will temporarily suspend its flights from Atyrau to Dubai starting June 28, due to a significant increase in flight duration.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment